Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis

Xue Chen, Aimin Jiang, Rui Zhang, Xiao Fu, Na Liu, Chuchu Shi, Jingjing Wang, Xiaojiang Zheng, Tao Tian, Xuan Liang, Zhiping Ruan and Yu Yao*

Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Background: Immune checkpoint inhibitors (ICIs) have achieved acknowledged progress in cancer therapy. However, ICI-associated cardiotoxicity as one of the most severe adverse events is potentially life-threatening, with limited real-world studies reporting its predictive factors and prognosis. This study aimed to investigate the real-world incidence, risk factors, and prognosis of ICI-related cardiotoxicity in patients with advanced solid tumors.

Methods: Electronic medical records from patients with advanced solid tumors receiving ICIs in the First Affiliated Hospital of Xi’an Jiaotong University were retrospectively reviewed. All patients were divided into the cardiotoxicity group and control group, with logistic regression analysis being implemented to identify potential risk factors of ICI-related cardiotoxicity. Furthermore, survival analysis was also performed to investigate the prognosis of patients with ICI-related cardiotoxicity.

Results: A total of 1,047 participants were enrolled in this retrospective study. The incidence of ICI-related cardiotoxicity in our hospital is 7.0%, while grade 3 and above cardiotoxicity was 2.4%. The logistic regression analysis revealed that diabetes mellitus [odds ratio (OR): 1.96, 95% confidence Interval (CI): 1.05–3.65, p = 0.034] was an independent risk factor, whereas baseline lymphocyte/monocyte ratio (LMR) (OR: 0.59, 95% CI: 0.36–0.97, p = 0.037) was the protective factor of ICI-related cardiotoxicity. Survival analysis indicated that severe cardiotoxicity (≥ grade 3) was significantly correlated with bleak overall survival (OS) than mild cardiotoxicity (≤ grade 2) (8.3 months vs. not reached, p = 0.001). Patients with ICI-related overlap syndrome had poorer overall survival than patients with mere cardiotoxicity (9.4 vs. 24.7 months, p = 0.033). However, the occurrence of ICI-related cardiotoxicity was not significantly associated with the OS of overall population with solid tumors. Subgroup analysis showed that lung cancer and PD-L1 usage were significantly correlated with a higher incidence of severe cases.

Conclusion: Immune checkpoint inhibitor-related cardiotoxicity is more common in the real-world setting than the previously published studies. Diabetes mellitus and baseline
INTRODUCTION

Immune checkpoint inhibitors (ICIs) mainly act on the activation of T cells to fight against tumor cells. There are currently FDA-approved drugs that target cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death ligand 1 (PD-L1). Although ICI-related adverse effects are overall less severe than chemotherapy, there are potentially lethal adverse effects, such as cardiotoxicity, neuromuscular toxicity, and pulmonary toxicity.

The first case of fatal ICI-related myocarditis was reported by Läubli et al. in 2015 (1), in a 73-year-old patient with metastatic melanoma who developed ICI-associated myocarditis after receiving pembrolizumab, leading to acute heart failure. Two cases of fulminant myocarditis were reported in 2016. Both patients became symptomatic within 2 weeks of administration and aggravated rapidly, leading to death within a short period despite the admission of high-dose glucocorticoid and supportive care. These two cases of severe cardiotoxicity warned clinicians of the security of ICIs (2).

Cardiotoxicity associated with ICIs is broadly classified into myocarditis, pericarditis, and arrhythmia. Other clinical manifestations, such as hypertension, Takotsubo-like syndrome, myocardial ischemia, and myocardial infarction, are less reported (3, 4). In addition, some studies have roughly divided them into inflammatory (including myocarditis, pericarditis, etc.) and non-inflammatory (arrhythmia, myocardial infarction, etc.).

Early studies showed that the incidence of ICI-related cardiotoxicity is less than 1% (5). However, as Ganatra et al. (6) stated, the increasing application of ICIs in real-world and the diverse presentation of cardiotoxicity suggest a higher incidence of cardiotoxicity than previously reported. In addition, subclinical cases and increased awareness of toxicity may also be the contributing factors. Among these classifications, myocarditis maintained the highest incidence and fatality rate, as well as the worst prognosis. However, the presentations of cardiotoxicity in real-world were not separated. It is not rare for myocarditis to occur simultaneously with arrhythmia or pericarditis. Studies have found that approximately 19% of patients with pathologically defined cardiotoxicity developed arrhythmias (7). Two patients with fulminant myocarditis reported in 2016 also developed complete atrioventricular conduction block (2). The pathophysiological manifestation suggested the infiltrated T cells and macrophages in the conduction system. As reported, atrial fibrillation, ventricular arrhythmias, and conduction disturbances were detected in 17–30% of patients with ICI-related cardiotoxicity, of whom 3–13% had mere arrhythmias without myocarditis (8). Although the mechanism is unclear, the investigators concluded that there may be underlying undiagnosed myocarditis (8).

Keywords: solid tumor, cardiotoxicity, rechallenge, risk factors, immune checkpoint inhibitor (ICI), prognosis
Immune checkpoint inhibitor-related pericarditis and arrhythmia were diagnosed according to Naranjo score. Suspected patients who suffered from cardiac damage during ICI therapy with a Naranjo scores ≥ 5 were included in the cardiotoxicity group.

Patients were categorized as “severe” cardiotoxicity if they displayed a grade 3–5 toxicity according to criteria adapted from the Common Terminology Criteria for Adverse Events V.5.0 (Table 1). Patients were categorized as “mild” cardiotoxicity if they displayed a grade 1–2 toxicity.

Statistical Analysis
Continuous variables are statistically described by means ± standard deviation (subject to normal distribution) or interquartile spacing (not subject to normal distribution); categorical variables are expressed in terms of number and percentage of cases. The SW test was used for the normality test, and one-way ANOVA was used for the variance homogeneity test. If the continuous variable obeys the normal distribution and one-way ANOVA was used for the variance homogeneity or interquartile spacing (not subject to normal distribution); and 48 patients with mild cardiotoxicity (cardiotoxicity, including 25 patients with severe cardiotoxicity developed cardiotoxicity, and 73 patients developed ICI-related adverse effects of different systems, and the presence of one toxicity may warn of another that may be more serious.

Ethical Approval and Informed Consent
This study was conducted in strict accordance with the requirements of the Declaration of Helsinki. Our research also passed the ethics review of the First Affiliated Hospital of Xi’an Jiaotong University (no: XJTU1AF2020LSK-262).

RESULTS

Characteristics of the Whole Population
From January 2020 to July 2021, a total of 1,492 patients with advanced solid tumors were hospitalized and treated with ICIs in the departments of medical oncology, surgical oncology, and radiation oncology. A total of 391 patients who did not meet the requirements were excluded, and a total of 1,101 patients who met the research criteria were screened. There were 127 patients with cardiac damage, of which 54 patients did not meet the diagnostic criteria. In the end, 974 patients did not suffer from cardiotoxicity have a lower lymphocyte ratio than patients without cardiotoxicity. But the difference was not statistically significant (p = 0.066). In addition, our research showed that the occurrence of ICI-related pneumonia (p = 0.005) and thyroid dysfunction (p < 0.005) during the course of ICI treatment were significantly associated with the occurrence of cardiotoxicity. Although most of the other two toxicities appear before cardiotoxicity, we cannot yet explain the relationship between ICI-related cardiotoxicity and ICI-related pneumonia or thyroid dysfunction. But this correlation suggests a link between adverse effects of different systems, and the presence of one toxicity may warn of another that may be more serious.

The univariate logistic regression analysis found that combined diabetes (OR = 2.05, 95% CI: 1.07–3.71, p = 0.023) may be a risk factor for cardiotoxicity, whereas lower baseline LMR (OR = 0.58, 95% CI: 0.35–0.93, p = 0.027) may be a protective factor (Figure 1). Ultimately, the multivariate regression analysis suggested that diabetes (OR = 1.96, 95% CI: 1.05–3.65, p = 0.034) was an independent risk factor for
the occurrence of ICI-related cardiotoxicity. In addition, lower baseline LMR (OR = 0.59, 95% CI: 0.36–0.97, \( p = 0.037 \)) was a protective factor (Figure 1).

**Severity of Myocarditis**

The population with ICI-related cardiotoxicity included 48 mild cases and 25 severe cases (Table 3). Among them, 4 patients (5%) died in hospital. All in-hospital died patients were severe cardiotoxicity. When cardiotoxicity occurs, echocardiography was abnormal in 20 cases (26.3%), mainly with abnormal wall motion. A total of 24 patients (31.6%) had an abnormal electrocardiogram, including ST-T abnormality, conduction block, and other changes. In addition, 30 patients (41.1%) in the subgroup suffered from cardiotoxicity and concurrent ICI damage of other systems, among which abnormal liver function, myositis, skin rash, and abnormal thyroid function were more common.

Cardiotoxicity happened mainly in men (56, 76.7%). In terms of cancer types, the proportion of severe cases in respiratory tumors was significantly higher than in other tumors (\( p = 0.045 \)), whereas the proportion in digestive tumors was significantly lower than other tumors (\( p = 0.014 \)). The ICI agents were mainly PD-1 (65, 89.0%), of which 19 cases (29.2%) were severe, whereas 8 cases received PD-L1, and 6 cases (75.0%) were severe. The difference between the two groups was statistically significant (\( p = 0.008 \)). We did not find that inflammatory parameters, such as NLR, PLR, and LMR, were associated with the severity of cardiotoxicity. Other indicators, including ECOG score, comorbidities, smoking history, family history, prior antitumor therapy, and treatment mode, were not significantly associated with the severity of cardiotoxicity. In addition, unlike the general population, the occurrence of ICI-related thyroid dysfunction (\( p = 0.120 \)) and ICI-related pneumonia (\( p = 0.327 \)) was not significantly associated with the severity of cardiotoxicity. There was no statistically significant difference in the occurrence time of mild and severe cardiotoxicities (median occurrence time: 105 vs. 134 days, \( p = 0.345 \)) (Figure 2).

**Survival Analysis**

Survival analysis was performed in patients with or without cardiotoxicity. We investigated the difference with overall survival in these patients. The median follow-up time was 19.0 months. There was no significant difference with median overall survival time (mOS) between the two groups without cardiotoxicity and those with cardiotoxicity (29.1 vs. 24.7 months, \( p = 0.184 \)) (Figure 3A). The mOS of severe cardiotoxicity was 8.3 months, while the mOS of mild cardiotoxicity was not reached (\( p = 0.001 \)) (Figure 3B).

Survival analysis was performed on the subgroups of patients with respiratory tumors and digestive tumors due to different prognoses of different tumor types. There was no statistically significant difference between the two groups with or without cardiotoxicity in the respiratory tumors (\( p = 0.360 \)) (Figure 4A). The mOS between the two groups without cardiotoxicity in the digestive system and those with cardiotoxicity was 21.6 and 15.3 months, respectively (Figure 4B). But the difference was also not statistically significant (\( p = 0.509 \)). For all patients with cardiotoxicity, mOS was 17.0 months.

In addition, we also compared the survival difference between the groups with mere cardiotoxicity and those with concurrent cardiotoxicity and other toxicities. The mOS with mere cardiotoxicity was 24.7 months, and the mOS in the group with overlap syndrome was 9.4 months (Figure 5A). The difference was statistically significant (\( p = 0.033 \)). In 2020, Dolladille et al. (10) analyzed the clinical characteristics of early and late cardiac adverse reactions through retrospective analysis of multicenter cases and data from the VigiBase using 90 days as a cutoff. They found differences in the characteristics of early and late cardiac toxicities. We furtherly plotted the survival curves of the two groups of patients with the occurrence time before 90 days and after 90 days. However, there was no significant difference between the two groups (Figure 5B).

**Immune Checkpoint Inhibitor Rechallenge**

Current guidelines suggest that restarting ICI is not recommended for grade 2 and above cardiotoxicity. We also strictly follow the recommendations in our clinical work. However, the complexity of real-world research results in patient diversity. In our study, some patients persisted in restarting ICI despite being fully informed of the risks. In the follow-up of patients who developed cardiotoxicity, there were 5 additional patients with grades 2 and 3 myocarditis who readmitted ICI after recovery (Figure 6). Only one of the five patients who

### Table 1 | Criteria for myocarditis severity scoring.

| Grade | Criteria |
|-------|----------|
| 1<sup>a</sup> | Elevated biomarkers without symptoms (e.g., dyspnea, chest pain, etc.) |
| 2 | Elevated biomarkers without symptoms but not requiring patient hospitalization |
| 3 | Elevated biomarkers without symptoms requiring patient hospitalization (not requiring intensive care unit level of care); abnormal cardiovascular diagnostic studies (echocardiography showing reduction in LV function or wall motion abnormalities; abnormal cardiac MRI) |
| 4 | Deterioration of grade 3 clinical status or requirement for ICU level of care for cardiac symptoms with evidence of decreased cardiac output (cardiogenic shock) or arrhythmia |
| 5 | Death of the patient refractory to medical therapy |

<sup>a</sup>CTCAEv5.0 released in 2017 does not include grade 1 myocarditis. But this criterion cannot reflect the whole situation of the occurrence of myocarditis. This table is based on Bonaca and CTCAEv4.0.

<sup>b</sup>Biomarkers for myocarditis are markers of myonecrosis, including cardiac troponin, CK-MB, or total CK.
### TABLE 2 | Characteristics of the whole population.

| Characteristics | Groups | Number of patients (ratio) | p-value |
|-----------------|--------|---------------------------|---------|
|                 | Without cardiotoxicity (N = 974) | With cardiotoxicity (N = 73) |         |
| Weight          | 62.2 ± 11.2 | 63.2 ± 9.4                | 0.447   |
| Age             | 59.5 ± 11.2 | 59.8 ± 11.7               | 0.835   |
| Gender          | Male 657 (67.5%) | 56 (76.7%) | 0.132   |
|                 | Female 317 (32.5%) | 17 (23.3%) |         |
| Cardiac disease | No 906 (93.0%) | 67 (91.8%) | 0.872   |
|                 | Yes 68 (7.0%) | 6 (8.2%) |         |
| Hypertension    | No 750 (77.0%) | 56 (76.7%) | 1.000   |
|                 | Yes 224 (23.0%) | 17 (23.3%) |         |
| Diabetes        | No 873 (89.6%) | 59 (80.8%) | 0.033   |
|                 | Yes 101 (10.4%) | 14 (19.2%) |         |
| Cigarette       | No 625 (64.2%) | 43 (58.9%) | 0.437   |
|                 | Yes 349 (35.8%) | 30 (41.1%) |         |
| Family history  | No 894 (91.8%) | 64 (87.7%) | 0.318   |
|                 | Yes 80 (8.2%) | 9 (12.3%) |         |
| Respiratory tumors | 329 (33.8%) | 31 (42.5%) | 0.159   |
| Digestive tumors | 467 (47.9%) | 29 (39.7%) | 0.183   |
| Urinary tract tumors | 74 (7.6%) | 9 (12.3%) | 0.173   |
| Malignant melanoma | 39 (4.0%) | 2 (2.7%) | 1.000   |
| Other tumors | No 906 (93.0%) | 67 (91.8%) | 0.872   |
|                 | Yes 68 (7.0%) | 6 (8.2%) |         |
| Prior chemotherapy | No 482 (49.5%) | 38 (52.1%) | 0.763   |
|                 | Yes 492 (50.5%) | 35 (47.9%) |         |
| Prior antiangiogenic therapy | No 837 (85.9%) | 62 (84.9%) | 0.950   |
|                 | Yes 137 (14.1%) | 11 (15.1%) |         |
| Lung metastasis | No 750 (77.0%) | 56 (76.7%) | 0.380   |
|                 | Yes 224 (23.0%) | 17 (23.3%) |         |
| Liver metastasis | No 731 (75.1%) | 48 (65.8%) | 0.106   |
|                 | Yes 243 (24.9%) | 17 (24.2%) |         |
| Brain metastasis | No 909 (93.3%) | 72 (98.6%) | 0.121   |
|                 | Yes 65 (6.7%) | 1 (1.4%) |         |
| Bone metastasis | No 764 (78.4%) | 60 (82.2%) | 0.544   |
|                 | Yes 210 (21.6%) | 13 (17.8%) |         |
| ECOG            | 0–1 803 (82.4%) | 63 (86.3%) | 0.496   |
|                 | 2–3 171 (17.6%) | 10 (13.7%) |         |
| Treatment       | ICI monotherapy | 66 (6.8%) | 6 (8.2%) | 0.818   |
|                 | ICI combined with chemotherapy | 908 (93.2%) | 67 (91.8%) | 0.463   |
| ICI agent       | PD-1 898 (92.2%) | 65 (90.0%) |         |
|                 | PD-L1 76 (7.8%) | 8 (11.0%) |         |
| LDH (U/L)       | <250 505 (70.0%) | 41 (70.7%) | 1.000   |
|                 | ≥250 216 (30.0%) | 17 (29.3%) |         |
| CK (U/L)        | <310 701 (98.9%) | 56 (98.2%) | 1.000   |
|                 | ≥310 8 (1.1%) | 1 (1.8%) |         |
| CK-MB (U/L)     | <24 599 (84.5%) | 45 (78.9%) | 0.362   |
|                 | ≥24 110 (15.5%) | 22 (21.1%) |         |
| Hemoglobin (g/L; normal range 115–150) | 126.7 ± 19.9 | 129.2 ± 18.8 | 0.296   |
| Platelet count (x10³/L; normal range 150–450) | 234.3 ± 97.0 | 214.3 ± 98.5 | 0.091   |
| White-cell count (x10³/L; normal range 4.0–10.0) | 6.9 ± 3.3 | 6.9 ± 2.6 | 0.892   |
| Neutrophil count (x10³/L; normal range 1.8–6.3) | 4.9 ± 3.6 | 4.9 ± 2.5 | 0.937   |
| Lymphocyte count (x10³/L; normal range 1.1–3.2) | 1.4 ± 0.6 | 1.4 ± 0.5 | 0.203   |
| Monocytes (x10³/L; normal range 0.1–0.6) | 0.4 ± 0.2 | 0.5 ± 0.4 | 0.166   |
| Eosinophils (x10³/L; normal range 0.02–0.52) | 0.2 ± 0.5 | 0.2 ± 0.3 | 0.482   |
| Albumin (g/L; normal range 30–50) | 39.2 ± 4.6 | 38.7 ± 4.6 | 0.379   |
| Globulin (g/L; normal range 20–40) | 29.5 ± 5.2 | 29.5 ± 5.0 | 0.958   |
| TC (mmol/L; 3.10–5.69) | 4.3 ± 1.0 | 4.5 ± 1.3 | 0.428   |
| PLR              | 197.3 ± 156.9 | 183.3 ± 116.8 | 0.341   |
| NLR              | 4.2 ± 4.6 | 4.4 ± 4.2 | 0.653   |
| LMR              | 3.9 ± 3.4 | 3.3 ± 1.7 | 0.010   |
| A/G              | 1.4 ± 0.3 | 1.3 ± 0.3 | 0.442   |
| Neutrophil ratio (normal range 0.75–7.5) | 68.8 ± 39.6% | 68.7% ± 10.0% | 0.923   |
| Lymphocyte ratio (normal range 20–50%) | 23.0% ± 10.2% | 21.1% ± 8.3% | 0.066   |

ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; LDH, lactate dehydrogenase; CK, creatine kinase; TC, total cholesterol; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; A/G, albumin to globulin ratio.

Continuous variables are expressed as mean and standard deviation.

Others include skin tumors, mediastinal tumors, head and neck tumors, genital neoplasm, sarcomas, and other tumor types.
had grade 3 myocarditis suffered grade 2 myocarditis after the rechallenge of ICI. No other grade 3 and above ICI toxicity were found in all patients. Following up for more than 1 year, only one case died of disease progression. The remaining patients were all alive. According to our investigation, the ICI rechallenge seems relatively secure. However, considering the small sample size in our cohort, more relevant studies are needed in the future to identify the safety of ICI rechallenge.
TABLE 3 | Characteristics of patients with cardiotoxicity.

| Characteristics       | Groups ≤ Grade 2 (N = 48) | Groups ≥ Grade 3 (N = 25) | p-value |
|-----------------------|----------------------------|---------------------------|---------|
| Age                   | ≤65 years old              | 33 (68.8%)                 | 16 (64%)| 0.883   |
|                       | ≥65 years old              | 15 (31.2%)                 | 9 (36%) |         |
| Gender                | Male                       | 38 (79.2%)                 | 18 (72%)| 0.692   |
|                       | Female                     | 10 (20.8%)                 | 7 (28%) |         |
| ECOG                  | 0–1                        | 43 (89.6%)                 | 20 (80%)| 0.440   |
|                       | 2–3                        | 5 (10.4%)                  | 5 (20%) |         |
| Cardiac disease       | No                         | 44 (91.7%)                 | 23 (92%)| 1.000   |
|                       | Yes                        | 4 (8.3%)                   | 2 (8%)  |         |
| Diabetes              | No                         | 38 (79.2%)                 | 21 (84%)| 0.854   |
|                       | Yes                        | 10 (20.8%)                 | 4 (16%) |         |
| Respiratory tumors    |                            |                           |         |         |
| Digestive tumors      |                            |                           |         |         |
| Urinary tract tumors  |                            |                           |         |         |
| Malignant melanoma    |                            |                           |         |         |
| Other tumors          |                            |                           |         |         |
| Treatment\(^a\)       | ICI monotherapy            | 4 (8.3%)                   | 2 (8%)  | 1.000   |
|                       | ICI combined with chemotherapy | 44 (91.7%)          | 23 (92%)|         |
| ICI                   | PD-1                       | 46 (95.8%)                 | 19 (76%)| 0.029   |
|                       | PD-L1                      | 2 (4.2%)                   | 6 (24%) |         |
| Neutrophil count (× 10\(^9\)/L; normal range 1.8–6.3) | <6.3 | 38 (79.2%) | 21 (84%) | 0.854 |
|                       | ≥6.3                       | 10 (20.8%)                 | 4 (16%) |         |
| Lymphocyte count (× 10\(^9\)/L; normal range 1.1–3.2) | <1.1 | 14 (29.2%) | 9 (36%) | 0.741 |
|                       | ≥1.1                       | 34 (70.8%)                 | 16 (64%)|         |
| Monocytes (10\(^9\)/L; normal range 0.1–0.6) | <0.6 | 35 (72.9%) | 22 (88%) | 0.238 |
|                       | ≥0.6                       | 13 (27.1%)                 | 3 (12%) |         |
| PLR                   | <163.1                     | 28 (58.3%)                 | 13 (52%)| 0.788   |
|                       | ≥163.1                     | 20 (41.7%)                 | 12 (48%)|         |
| NLR                   | <3.1                       | 20 (41.7%)                 | 12 (48%)| 0.788   |
|                       | ≥3.1                       | 28 (58.3%)                 | 13 (52%)|         |
| LMR                   | <3.4                       | 31 (64.6%)                 | 14 (56%)| 0.644   |
|                       | ≥3.4                       | 17 (35.4%)                 | 11 (44%)|         |
| A/G                   | <1.5                       | 36 (75%)                   | 16 (64%)| 0.476   |
|                       | ≥1.5                       | 12 (25%)                   | 9 (36%) |         |
| Neutrophil ratio (normal range 40–75%) | <70% | 22 (45.8%) | 14 (56%) | 0.563 |
|                       | ≥70%                       | 26 (54.2%)                 | 11 (44%)|         |
| Lymphocyte ratio (normal range 20–50%) | <20% | 22 (45.8%) | 11 (44%) | 1.000 |
|                       | ≥20%                       | 26 (54.2%)                 | 14 (56%)|         |

ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; A/G, albumin to globulin ratio.

\(^a\) Others include prostatic cancer, mediastinal tumor, head and neck squamous cell carcinoma, sarcoma.

DISCUSSION

We found that the incidence of cardiotoxicity was 7.0%, which was higher than the previously reported. By collecting the cardiovascular risk factors of the enrolled patients, we found that diabetes was an independent risk factor for the occurrence of cardiotoxicity. This conclusion can be seen in the retrospective study of Mahmood et al. (11). Through a multicenter retrospective study of 35 patients, they found that myocarditis was more common in patients with diabetes mellitus, especially in patients receiving a combination of ICI therapy. Although they ultimately failed to prove it an independent risk factor, their research suggested a certain direction. In our analysis, an exact association of diabetes with the development of cardiotoxicity was found. However, we did not find an association between other cardiovascular risk factors, such as hypertension and the occurrence of cardiotoxicity.

The effect of diabetes on the development of ICI-related cardiotoxicity may be related to the long-term chronic inflammation in patients with diabetes. Till now, diabetes has been regarded as a chronic inflammatory disease. The high-glucose environment of diabetes significantly increases the cytokines, such as interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 13 (IL-13), and tumor necrosis factor α (TNF-α). These cytokines maintained the balance of the autoimmune microenvironment. The chronic pathological state of immune imbalance caused by diabetes can promote many diseases (12–14). In addition, the oxidative stress produced by diabetes can also produce many inflammatory cytokines, such as TNF-α, IL-6, and transforming growth factor β (14).
The cytokine pathway has been confirmed to be closely related to irAEs in many studies (15). In addition, diabetes affects the number and activity of T cells, B cells, and NK cells in peripheral blood, and the result of immune imbalance may also play an important role (14). Moreover, whether diabetes, as an autoimmune disease, also plays an important role in irAEs like other types of autoimmune diseases remains to be further studied.

We also collected baseline inflammatory indicators, such as IL-6, C-reactive protein (CRP), and lactic dehydrogenase (LDH), of all patients and calculated NLR, PLR, and LMR. We found that lower baseline LMR was an independent risk factor for the development of cardiotoxicity. In previous studies, the correlation between peripheral lymphocyte levels and adverse reactions has already been investigated. In a study of risk factors for cardiotoxicity based on more than 4,000 immunotherapy patients (16), the authors identified the association between low baseline peripheral lymphocyte levels and cardiotoxicity through a machine learning method. In a retrospective study of NSCLC, an association of LMR with irAEs was also found (17). Activated T lymphocytes in patients with tumors after using PD-1/PD-L1 antibodies can not only attack tumor cells, but also cause irAEs. According to the autopsy result of patients with cardiotoxicity as previously reported, lymphocytic infiltration was widely seen in the diseased tissue (2). Therefore, lymphocytes may play a key role in the response of irAEs. However, no direct correlation between peripheral lymphocyte count (or percentage) and the occurrence of cardiotoxicity was found in our cohort. Moreover, these indicators are often dynamic during tumor treatment. Therefore, how does their changing act on adverse reactions? What role do lymphocytes play in it? They deserve further discussion.

In terms of gender, ICI was used in more men than women in our study, possibly due to the higher tumor prevalence in male patients. In this study, male patients received ICI proportionally more often than female patients, but no significant association between gender and the development of myocarditis was found. One study found higher occurrence rate of ICI associated cardiovascular with men (18). Several additional studies had the same finding (7, 11, 19). However, another research found a different result that women were at higher risk of ICI-related myocarditis. These studies suggested the relationship of gender and the occurrence of ICI-related myocarditis. In addition, we found a higher incidence of ICI-related cardiotoxicity in patients with respiratory neoplasms than in other types of neoplasms. Salem et al. (7) also found a higher rate of ICI-related pericardial disease among patients with lung cancer. Basic research has found upregulation of PD-L1 in models of myocardial injury induced by ischemiareperfusion and hypothermia, which may be a cytokine-mediated mechanism of cardiac protection. Besides, radiation therapy in patients with lung cancer may present with potential exposure to cardiac antigens. Immune activation thereby conferring them a higher incidence of cardiotoxicity. As for the correlation between comorbid autoimmune diseases and cardiotoxicity, there were numerous
reports of thymoma patients with ICI-related cardiotoxicity. Toi et al. (20) retrospectively recruited 137 patients with positive autoimmune antibody receiving ICI therapy. They found that positive autoimmune antibody was significantly associated with a higher occurrence of irAEs and better clinical benefit in NSCLC. In addition, another study also suggested
a relationship between autoimmune antibodies and irAEs (20). Therefore, we are more cautious about ICI initiation in patients with autoimmune diseases in real-world. Therefore, patients with active autoimmune disease were excluded from our study. Because the treatment of active autoimmune diseases is contrary to tumor treatment, they can affect the judgment to response of tumor treatment and drug-related adverse reactions.

In addition to ICI-related cardiotoxicity, we also collected ICI-related thyroid dysfunction and pneumonia. We found that both of them have a certain correlation with the occurrence of cardiotoxicity. Although the onset of ICI-related pneumonitis or abnormal thyroid function does not completely precede the onset of cardiotoxicity, we cannot establish a causal relationship between them. However, this finding suggests that there may be a link between the toxicities occurring at different times targeting different organs. The occurrence of toxicities targeting the lung or thyroid may then alert clinicians the occurrence of cardiotoxicity. Besides, myositis, hepatitis, and pneumonia may be complicated by the occurrence of cardiotoxicity. In the cardiotoxicity population, a total of 30 (41.1%) patients had concurrent toxicities targeting other organs. In a study based on the VigiBase database, serious combined ICI-related adverse reactions accounted for 42% of adverse reactions, most of which were ICI-related myocarditis and myositis (21). In a multicenter study, 32% of myositis was associated with concurrent myocarditis (22). In addition, the mortality rate is the highest in patients with combined myocarditis and myasthenia gravis. Therefore, in patients with symptoms of ICI-related myositis, they should be alert to the occurrence of myocarditis.

Previous studies have demonstrated a possible correlation between irAEs and tumor prognosis. A meta-analysis (23) explored the relationship between ICI-related adverse drug reactions and clinical benefits. It was suggested that in patients receiving ICIs, the development of irAEs was positively correlated with objective remission rate (ORR), progression-free survival (PFS), and OS, irrespective of disease site, type of ICI, and irAE. ORR was better in patients with grade 3 or higher toxicity, but OS was worse. However, in this study, we only did the analysis in overall survival, and no significant difference was found between patients with or without cardiotoxicity.

Till now, the National Comprehensive Cancer Network (NCCN) guidelines do not recommend rechallenge of ICI after grade 2 and above myocarditis. Subclinical myocarditis was recommended continue the use of ICI with close detection. In a single-center retrospective study in 2019 (24), the investigators included 93 patients with grade 2 or higher toxicity, including 43 grade 2 events, 36 grade 3 events, and 14 grade 4 events. Taking the occurrence of the second toxicity as the endpoint, the final results suggested that the time since ICI use to the occurrence of the initial irAE was related to the occurrence of the second irAE. Besides, the severity of the second irAE was not more severe than the first one. They concluded that the risk-reward ratio of anti-PD-1 or anti-PD-L1 rechallenge appears to be acceptable. However, patients with first ICI-related toxicity involving the heart were not included in this study. Conversely, there were also some studies restarting ICI after the occurrence of irAEs, resulting in recurrence of grade 5 toxicity in patients. Therefore, ICI rechallenge after irAEs is still controversial. Due to the small number of cases in our study, we cannot currently explain the safety of cardiotoxicity after restarting, because once cardiotoxicity occurs, it may be fatal drug toxicity, which is unacceptable for clinicians and patients’ families. Moreover, the timing of ICI restarting among these patients also varied, and some patients even resumed ICI 1 month after ICI withdrawal. If there are large clinical studies to confirm the feasibility of restarting immunotherapy for ICI-related cardiotoxicity, the timing of restarting ICI will also be a major focus. Furthermore, there were many patients with grade 1 cardiotoxicity who continue to use immunotherapy under strict monitoring, and a small number of patients who suffered mild cardiotoxicity for not one time, but it does not affect the progress of tumor treatment.

CONCLUSION

We retrospectively analyzed the risk factors of ICI-related cardiotoxicity in the whole population receiving ICI therapy. We found a higher incidence of ICI-related cardiotoxicity, and a high proportion of severe cases than previous reported in real-world situation. Patients with diabetes mellitus and low baseline levels of LMR have an increased incidence of cardiotoxicity, which should be closely monitored during the use of ICIs. Besides, the incidence of severe cardiotoxicity was correlated with shorter overall survival.

SHORTAGE

Despite the advantages and potential insights on this study, there are some inevitable shortcomings in our study. First of all, some potential biases are still unavoidable due to the retrospective design of this study, such as investigator bias. Second, although the overall immunotherapy sample size we included is relatively large, the number of cardiotoxicity cases is relatively small, as well as the number of patients who rechallenge ICI. Finally, due to the serious lack of some data during the study period, we could not analyze the relationship between the baseline levels of some inflammatory markers (such as LDH, CRP, and cytokines) and the occurrence of cardiotoxicity. Hence, well-designed large-scale prospective studies are urgently needed in the future.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
ETHICS STATEMENT

This study involving human participants was reviewed and approved by the Ethics Review of the First Affiliated Hospital of Xi’an Jiaotong University (no. JXTU1AF2020LSK-262) and was conducted in strict accordance with the requirements of the Declaration of Helsinki. Written informed consent was not required due to the retrospective nature of the study.

REFERENCES

1. Läubli H, Balmelli C, Bossard M, Pfister O, Glatt K, Zippeius A. Acute heart failure due to autoimmune myocarditis during pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. (2015) 3:11. doi: 10.1186/s40425-015-0057-1
2. Johnson DB, Ballo JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. (2016) 375:1749–55. doi: 10.1056/NEJMoa1609214
3. Geisler BP, Raad RA, Esain D, Sharon E, Schwartz DR. Apical Ballooning and Cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer. (2015) 3:4. doi: 10.1186/s40425-015-0048-2
4. Nykl R, Fischer O, Vykoupil K, Taborsky M. A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior stem) - systemic inflammatory response syndrome after use of pembrolizumab. Arch Med Sci Atheroscler Dis. (2017) 2:e100–2. doi: 10.5114/amsad.2017.72531
5. Upadhrastra S, Elias H, Patel K, Zheng L. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med. (2019) 5:6–14. doi: 10.1016/j.cdtm.2019.02.004
6. Ganastra S, Neian TG. Immune checkpoint inhibitor-associated myocarditis. Oncologist. (2018) 23:879–86. doi: 10.1634/theoncologist.2018-0130
7. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. (2018) 19:1579–89. doi: 10.1016/s1470-2045(18)30608-9
8. Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. (2017) 136:2085–7. doi: 10.1161/circulationaha.117.030571
9. Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. (2019) 140:80–91. doi: 10.1161/circulationaha.118.034947
10. Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. (2020) 8:e000261. doi: 10.116/j/jitc.2019-000261
11. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. (2018) 71:1755–64. doi: 10.1016/j.jacc.2018.02.037
12. Parikh RB, Min EJ, Wileyto EP, Riaz F, Gross CP, Cohen RB, et al. Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers. JAMA Oncol. (2021) 7:1843–50. doi: 10.1001/jama oncology.2021.4971
13. Tanaka S, Isoda F, Ishihara Y, Kimura M, Yamakawa T, T Lymphopaenia in relation to body mass index and TNF-alpha in human obesity: adequate weight reduction can be corrective. Clin Endocrinol (Oxf). (2001) 54:347–54. doi: 10.1046/j.1365-2265.2001.1139cn2155.x
14. Dong G, Li Y, Zhao Q, Pang B, Qiu X, Wei J, et al. Effects of diabetes on the development of radiation pneumonitis. Respir Res. (2021) 22:160. doi: 10.1186/s12931-021-01754-4
15. Kang JH, Blustone JA, Young A. Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines. Trends Immunol. (2021) 42:293–311. doi: 10.1016/j.it.2021.02.006
16. Heilbroner SP, Few R, Mueller J, Chalwa J, Charest F, Suryadvara S, et al. Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach. J Immunother Cancer. (2021) 9:e002545. doi: 10.1136/jitc-2021-002545
17. Egami S, Kawase H, Hashimoto H, Uozumi R, Arami T, Sakiyama N, et al. Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study. J Cancer. (2021) 12:2105–12. doi: 10.7150/jca.5 3242
18. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. (2018) 4:1721–8. doi: 10.1001/jamaoncol.2018.3923
19. Reuben A, Petaccia de Macedo M, McQuade J, Joon A, Ren Z, Calderone T, et al. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology. (2017) 6:e1361097. doi: 10.1080/2162402x.2017.1361097
20. Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, et al. Profiling preexisting antibodies in patients treated with Anti-Pd-1 therapy for advanced non-small cell lung cancer. JAMA Oncol. (2019) 5:376–83. doi: 10.1001/ jamaoncol.2018.5860
21. Mosleh JI, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. J Immunother Cancer. (2018) 391-933. doi: 10.1001/doi-04-7636f(18)30533-6
22. Moreira A, Loquai C, Pöhler C, Kahler KE, Knauss S, Heppt MV, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer. (2019) 106:12–23. doi: 10.1016/j.ejca.2018.0 9.033
23. Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – a systematic review and meta-analysis. Cancer Treat Rev. (2021) 92:102134. doi: 10.1016/j.ctrv.2020.10 2134
24. Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. (2019) 5:1310–7. doi: 10.1001/jama oncology.2019.1022

AUTHOR CONTRIBUTIONS

XC, TT, XL, ZR, and YY contributed to the design of the study. XC, AJ, RZ, XF, NL, JW, and XZ contributed to manuscript preparation. XC and AJ wrote the manuscript. RZ, YY, CS, and XL helped collect cases. All authors contributed to the article and approved the submitted version.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chen, Jiang, Fu, Li, Shi, Wang, Zheng, Tian, Liang, Ruan and Yao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.